Assessment of Time to CAR-T Cell Therapy and Patients’ Outcomes in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Based on Insurance Status (Public Versus Private) and Distance Traveled to Treatment Center
2021 TCT | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR（2021）
Key words
insurance status,cell therapy,b-cell
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined